Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncology Pharma Inc (OP:ONPH)

0.0514 +0.0002 (+0.39%)
Streaming Delayed Price Updated: 3:24 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,107
Open 0.0512
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0512
Today's Range 0.0512 - 0.0649
52wk Range 0.0001 - 0.3640
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
World Awaits Bankman-Fried Sentence, Drug Stock Pump-And-Dump, Penny Stock Fraud: Financial Crimes Weekly ↗
Prosecutors push for harshest punishment for Sam Bankman-Fried, convicted on fraud charges in FTX collapse. Defense seeks leniency. 
Via Benzinga
Topics Fraud Lawsuit
News headline image
Oncology Pharma Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is furthering progress in discussions with investors and developing the... 
From Oncology Pharma Inc.
Via AccessWire

Performance

YTD
+1185.0%
+1185.0%
1 Month
-25.5%
-25.5%
3 Month
-25.6%
-25.6%
6 Month
+367.3%
+367.3%
1 Year
+25600.0%
+25600.0%

More News

Read More
News headline image
Oncology Pharma Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Announces: Initial Feasibility Study of the Nanoemulsion Drug Delivery System is Complete and Results Have Met the Threshold for Moving Forward To the Next Steps of Development
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Advances Progress on Multiple Fronts Including Advanced Attention to Connect2Trials' Commercial Development
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Completes Feasibility Phase of its Licensed Nanoemulsion Drug Delivery System to Treat Cancer
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Reports on Progress with Ribera Solutions
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Releases Further Feasibility Studies, Data and Capacities
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Expands on Feasibility Studies and Data
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Gives Update on Technology, Formulation and Data Creation
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma's New Year Update
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Meeting Towards Future Developments
From Oncology Pharma Inc.
Via AccessWire
News headline image
Oncology Pharma Year End Review and Outlook
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma Research and Vision
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma Reveals Plans for Development of Lead Cancer Drug Candidate
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Gives Update on Ongoing Work and Progress
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Oncology Pharma, Inc. Update on PCAOB Audit Selection Process and License Agreement
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property
News headline image
Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties
From Oncology Pharma Inc.
Via AccessWire
Topics Intellectual Property

Frequently Asked Questions

Is Oncology Pharma Inc publicly traded?
Yes, Oncology Pharma Inc is publicly traded.
What exchange does Oncology Pharma Inc trade on?
Oncology Pharma Inc trades on the OTC Traded
What is the ticker symbol for Oncology Pharma Inc?
The ticker symbol for Oncology Pharma Inc is ONPH on the OTC Traded
What is the current price of Oncology Pharma Inc?
The current price of Oncology Pharma Inc is 0.0514
When was Oncology Pharma Inc last traded?
The last trade of Oncology Pharma Inc was at 09/11/26 03:24 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.